NC EUPHORA RAPID EXCHANGE BALLOON DILATATION CATHETER

K141090 · Medtronic, Inc. · LOX · Aug 15, 2014 · Cardiovascular

Device Facts

• Record ID: K141090
• Device Name: NC EUPHORA RAPID EXCHANGE BALLOON DILATATION CATHETER
• Applicant: Medtronic, Inc.
• Product Code: LOX · Cardiovascular
• Decision Date: Aug 15, 2014
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.5100
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The NC Euphora™ RX Balloon Dilatation catheter is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion. The balloon dilatation catheter is also indicated for post deployment expansion of balloon expandable stents.

Device Story

The NC Euphora RX is a rapid exchange PTCA balloon dilatation catheter used by interventional cardiologists in a clinical setting. The device consists of a catheter shaft with a distal balloon and a proximal female luer for connection to an inflation device. The operator advances the catheter over a guidewire to the target stenosis site, guided by radiopaque marker bands. The balloon is inflated to a specific pressure to dilate the artery or expand a stent, improving myocardial perfusion. The device features incremental improvements over the predicate, including lower radial growth and higher pressure ratings. It is provided sterile for single use.

Clinical Evidence

No clinical investigation was performed. Evidence consists of non-clinical in-vitro bench testing (including balloon fatigue, compliance, inflation/deflation time, bond strength, and coating integrity) and non-GLP in-vivo studies for radiopacity. Biocompatibility testing was conducted per ISO 10993-1 for limited exposure (<24 hours) devices, including cytotoxicity, sensitization, systemic toxicity, and hemocompatibility assays.

Technological Characteristics

Rapid exchange PTCA catheter; balloon diameters 2.0mm-5.0mm; lengths 6mm-27mm; nominal pressure 12atm; rated burst pressure 20atm. Features radiopaque marker bands and shaft markers. Sterilized via E-beam (ISO 11137, EN 556, TIR 33) to SAL 10^-6. Biocompatibility per ISO 10993-1 and ASTM standards for hemocompatibility.

Indications for Use

Indicated for patients requiring balloon dilatation of stenotic coronary arteries or bypass grafts to improve myocardial perfusion, and for post-deployment expansion of balloon-expandable stents.

Regulatory Classification

Identification

Standard PTCA Catheter: A PTCA catheter is a device that operates on the principle of hydraulic pressurization applied through an inflatable balloon attached to the distal end. A PTCA balloon catheter has a single or double lumen shaft. The catheter features a balloon of appropriate compliance for the clinical application, constructed from a polymer. The balloon is designed to uniformly expand to a specified diameter and length at a specific pressure as labeled, with well characterized rates of inflation and deflation and a defined burst pressure. The device generally features a type of radiographic marker to facilitate fluoroscopic visualization of the balloon during use. A PTCA catheter is intended for balloon dilatation of a hemodynamically significant coronary artery or bypass graft stenosis in patients evidencing coronary ischemia for the purpose of improving myocardial perfusion. A PTCA catheter may also be intended for the treatment of acute myocardial infarction; treatment of in-stent restenosis (ISR) and/or post-deployment stent expansion. Cutting/scoring PTCA Catheter: A cutting/scoring PTCA catheter is a balloon-tipped catheter with cutting/scoring elements attached, which is used in those circumstances where a high pressure balloon resistant lesion is encountered. A cutting/scoring PTCA catheter is intended for the treatment of hemodynamically significant coronary artery stenosis for the purpose of improving myocardial perfusion. A cutting/scoring PTCA catheter may also be indicated for use in complex type C lesions or for the treatment of in-stent restenosis.

Special Controls

*Classification.* Class II (special controls). The special control for this device is “Class II Special Controls Guidance Document for Certain Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheters.” See § 870.1(e) for the availability of this guidance document.(b) *Cutting/scoring PTCA Catheter* —(1)*Identification.* A cutting/scoring PTCA catheter is a balloon-tipped catheter with cutting/scoring elements attached, which is used in those circumstances where a high pressure balloon resistant lesion is encountered. A cutting/scoring PTCA catheter is intended for the treatment of hemodynamically significant coronary artery stenosis for the purpose of improving myocardial perfusion. A cutting/scoring PTCA catheter may also be indicated for use in complex type C lesions or for the treatment of in-stent restenosis.(2) *Classification.* Class III (premarket approval). As of May 28, 1976, an approval under section 515 of the act is required before this device may be commercially distributed. See § 870.3.

Predicate Devices

• Medtronic NC Sprinter® RX Balloon Dilatation Catheter (P790017/S095)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features an abstract design of three human profiles facing right, stacked on top of each other. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the top of the seal.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

August 14, 2014

Medtronic Inc. Ms. Gerardine Finn VP of Regulatory Affairs - Coronary and RDN Cardiac & Vascular Group 3576 Unocal Place Santa Rosa, CA 95403

Re: K141090

Trade/Device Name: NC Euphora Rapid Exchange Balloon Dilatation Catheter Regulation Number: 21 CFR 870.5100 Regulation Name: Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter Regulatory Class: Class II Product Code: LOX Dated: July 16, 2014 Received: July 18, 2014

Dear Ms. Finn,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device

{1}------------------------------------------------

related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

M. A. Hillebrenner

for

for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## Indications for Use

510(k) Number (if known) K141090

#### Device Name

NC Euphora™ Rapid Exchange Balloon Dilatation Catheter

#### Indications for Use (Describe)

The NC Euphora™ Rapid Exchange Balloon Dilatation catheter is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion. The balloon dilatation catheter is also indicated for post deployment expansion of balloon expandable stents.

Type of Use (Select one or both, as applicable)

2 Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

## PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

#### FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

{3}------------------------------------------------

# 510(k) Summary per 21 CRF 807.92

| Date Prepared: | August 15th, 2014 |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant: | Medtronic, Inc.<br>Medtronic Ireland<br>Parkmore Business Park West<br>Galway<br>Ireland |
| Official<br>Correspondent: | Caitriona Regan<br>Senior Regulatory Affairs Specialist<br>Medtronic Ireland<br>Parkmore Business Park West<br>Galway<br>Ireland<br>Phone: [phone]<br>Fax: [phone]<br>Email: [e-mail] |
| Proprietary<br>Name: | NC Euphora™ Rapid Exchange Balloon Dilatation Catheter |
| Common<br>Name: | Percutaneous Transluminal Coronary Angioplasty (PTCA)<br>Catheter |
| Device<br>Classification: | Class II (special controls) |
| Regulation<br>Number: | 21 CFR 870.5100 |
| Classification<br>Name: | Percutaneous Transluminal Coronary Angioplasty (PTCA)<br>Catheter |
| Product Code: | LOX |
| Device<br>Description: | The NC Euphora™ RX Balloon Dilatation catheter is a<br>Percutaneous Transluminal Coronary Angioplasty (PTCA) Rapid<br>Exchange System. The balloon at the distal end of the catheter<br>can be inflated to a defined diameter at a specific pressure as<br>defined in the product labelling. The proximal end of the catheter<br>has a female luer for attachment to an inflation device. The<br>catheter provides a lumen which enables the use of a guidewire to<br>position the catheter. Radiopaque balloon marker bands enable<br>accurate placement. Shaft markers for brachial and femoral<br>techniques are in place.<br>The NC Euphora device is available in balloon diameters of<br>2.0mm to 5.0mm and in balloon lengths of 6mm to 27mm. The<br>NC Euphora device has a nominal pressure of 12atm and a rated<br>burst pressure of 20atm. |
| Indications For<br>Use: | The NC Euphora™ RX Balloon Dilatation catheter is indicated<br>for balloon dilatation of the stenotic portion of a coronary artery<br>or bypass graft stenosis for the purpose of improving myocardial<br>perfusion. The balloon dilatation catheter is also indicated for<br>post deployment expansion of balloon expandable stents. |
| Substantially<br>Equivalent<br>Device: | The NC Euphora™ RX Balloon Dilatation Catheter is similar to<br>the following predicate device with respect to intended use,<br>design and technology:<br>Medtronic NC Sprinter® RX Balloon Dilatation Catheter<br>(P790017/S095, approved October 10, 2008) |
| Summary of<br>Technological<br>Differences to<br>the Predicate<br>Device: | The Euphora™ RX Balloon Dilatation Catheter represents a<br>series of incremental performance improvements over its<br>predicate device NC Sprinter® RX Balloon Dilatation Catheter,<br>with primary attributes including lower balloon radial growth and<br>higher nominal and rated burst pressure. The NC Euphora<br>catheter is also offered in more balloon sizes compared to its<br>predicate and the 2.0mm diameter size is indicated for post<br>deployment expansion of balloon expandable stents. |

{4}------------------------------------------------

{5}------------------------------------------------

| Summary of | Design Verification in-vitro testing: |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Non-Clinical<br>Data: | The following in-vitro bench tests were completed on the NC<br>EuphoraTM RX Balloon Dilatation Catheter in accordance with<br>the requirements of Guidance for Industry and FDA Staff - Class<br>II Special Controls Guidance Document for Certain<br>Percutaneous Transluminal Coronary Angioplasty (PTCA) |

- Effective length ●
performance specifications:

- Catheter Profile ●
- System Pressure Capability & System Pressure Capability (in ● Stent)

Catheters, September 8, 2010 and verify that it meets the required

- Balloon Fatigue & Balloon Fatigue (in Stent)
- Balloon Compliance ●
- Balloon Inflation and Deflation Time
- Catheter Bond Strength ●
- Coating Integrity
- Coating Particulate Evaluation ●
- Flexibility and Kink ●
- Torque Strength

## Pre-Clinical Study (non-GLP):

Medtronic Ireland conducted pre-clinical in-vivo (non-GLP) studies for evaluation of the Radiopacity attribute of the NC Euphora™ RX Balloon Dilatation Catheter.

## Biocompatibility Testing:

Biocompatibility testing for the NC Euphora™ RX Balloon Dilatation Catheter has been completed in accordance with the recommendations of Guidance for Industry and FDA Staff -Class II Special Controls Guidance Document for Certain Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheters, September 8, 2010 and International Standard ISO10993-1:2009, Biological Evaluation of Medical devices-Part 1: Evaluation and Testing for an external communicating device with limited exposure i.e. whose contact with circulating blood is ≤ 24 hours.

The following Biocompatibility tests were performed to support the NC Euphora™ RX Balloon Dilatation Catheter:

{6}------------------------------------------------

- Cytotoxicity Study using ISO MEM Elution method ●
- ISO Maximisation Sensitisation Study ●
- ISO Acute Intracutaneous Reactivity ●
- ISO Acute Systemic Toxicity ●
- USP Material Mediated Pyrogen Study in Rabbits
- In Vivo Thromboresistance Study .
- ASTM In-vitro Haemolysis ●
- ASTM Partial Thromboplastin Time (PTT) Coagulation ● Testing
- C3a Complement Activation Assay Study ●
- Sc5b-9 Complement Activation Assay Study ●
- USP Physicochemical Tests ●

The NC Euphora™ RX Balloon Dilatation Catheter met all specified design and performance requirements. No new safety or effectiveness issues were raised during the testing. The bench testing qualification and biocompatibility testing demonstrated that the subject device NC Euphora" RX Balloon Dilatation Catheter is substantially equivalent in terms of safety and effectiveness to the predicate device.

No clinical investigation has been performed for this device. Summary of

Clinical Data:

- Sterilization The NC Euphora™ RX Balloon Dilatation Catheter will be Validation: sterilized and validated for E-beam sterilization in accordance with ISO11137, EN556 and TIR33 to achieve a minimum Sterility Assurance Level (SAL) of 10-9.
- Through the data and information presented, Medtronic Ireland Conclusion: considers the NC Euphora™ RX Balloon Dilatation Catheter to be substantially equivalent to the predicate device.